Sandbox g12
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Drugs with possible TdP risk
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Amantadine (Symmetrel®, Symadine®)
- Hydroxychloroquine (Plaquenil®, Quineprox®)
- Itraconazole (Sporanox®, Onmel®)
- Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)
- Metronidazole (Flagyl® and many others)
- Nelfinavir (Viracept®)
- Posaconazole (Noxafil®, Posamol®)
- Quinine sulfate (Qualaquin®)
- Ritonavir (Norvir®)
- Telaprevir (Incivek®, Incivo®)
- Voriconazole (VFend®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)